Beringea and Arboretum Ventures have led a $10 million Series C funding round in Rethink, which provides web-based learning and care management tools for children with autism and other behavioral health disorders. Existing investors also joined the funding round. Michael Gross, managing director at Beringea, and Paul McCreadie, managing director at Arboretum Ventures, will join the company’s board.
Fidelis SeniorCare (“Fidelis” or the “Company”), a successful pioneer and leader in the delivery of extraordinary clinical health care services for seniors, announced the appointment of former WellCare Health Plans chief Alec Cunningham as their new President and Chief Executive Officer. Sam Willcoxon, Founder and former Chief Executive Officer, will remain with the company and assume the role of Chairman.
Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, reported financial results for the quarter ended June 30,2014.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2014.
Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced that Heather D. Rider has been elected to its Board of Directors, effective immediately.
Jan Garfinkle was nominated and featured in the 2014 Powered By Women issue of DBusiness Magazine as a female business leader in the region who is driving profits, adding employees and opening new opportunities.
NxThera, Inc., a medical device company developing technology to treat urologic diseases, announced completion of enrollment in its Rezūm II IDE clinical trial for the treatment of benign prostatic hyperplasia (BPH).